Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAWNASDAQ:NEXINASDAQ:NTHINASDAQ:VSAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.01+5.3%$0.02$0.06▼$0.33N/AN/A34,287 shs56,579 shsNEXINexImmune$0.05$0.00▼$7.05N/A1.987,749 shsN/ANTHINeonc Technologies$7.22-1.5%$7.76$4.11▼$25.00N/AN/A82,858 shs19,966 shsVSARVersartis$1.19$1.19$1.14▼$2.76N/AN/A479,436 shs349,963 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%-31.85%-47.47%-59.23%-89.37%NEXINexImmune0.00%0.00%0.00%-99.90%-100.00%NTHINeonc Technologies-1.50%-3.60%+24.48%+721,999,900.00%+721,999,900.00%VSARVersartis0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AVSARVersartisN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/ANEXINexImmune 0.00N/AN/AN/ANTHINeonc Technologies 0.00N/AN/AN/AVSARVersartis 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/ANTHINeonc Technologies$79.99KN/AN/AN/AN/AN/AVSARVersartisN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ANEXINexImmune-$32.34M-$18.54N/AN/AN/AN/A-534.32%-213.72%N/ANTHINeonc TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AVSARVersartisN/AN/A0.00∞N/AN/AN/AN/AN/ALatest VSAR, AEHAW, NTHI, and NEXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025NTHINeonc TechnologiesN/A-$2.10N/A-$2.10N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/AVSARVersartisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEHAWAesther Healthcare AcquisitionN/AN/AN/ANEXINexImmuneN/A0.660.66NTHINeonc TechnologiesN/AN/AN/AVSARVersartisN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/ANEXINexImmune9.85%NTHINeonc TechnologiesN/AVSARVersartis38.52%Insider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/ANEXINexImmune14.90%NTHINeonc TechnologiesN/AVSARVersartis10.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableNEXINexImmune61.40 million1.19 millionNot OptionableNTHINeonc Technologies8N/AN/AN/AVSARVersartisN/AN/AN/AOptionableVSAR, AEHAW, NTHI, and NEXI HeadlinesRecent News About These CompaniesISRO Announces Launch Date For Venus Orbiter Mission | All About Shukrayaan-1October 3, 2024 | outlookindia.comGrowth hormone could be filed without further trials, says OPKOSeptember 24, 2024 | pharmaphorum.com16 Biopharma Companies Besides Medivation That Are Attractive TargetsJuly 21, 2023 | thestreet.comJohn Newman's Stock Ratings - BenzingaMay 11, 2023 | news.google.comGlobal Human Growth Hormone Market Assessment 2023-2030 ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comHDAX THERAPEUTICS ANNOUNCES APPOINTMENT OF DRS ... - InvestorsObserverApril 11, 2023 | news.google.comHuman Growth Hormones Deficiency (Ghd) Drug Market 2023 with Growth Overview, Developments in Manufacturing Te - openPRMarch 28, 2023 | news.google.comHuman Growth Hormones Deficiency (Ghd) Drug Market is booming ... - Trending in PakistanFebruary 15, 2023 | news.google.comInjured snowmobiler rescued from Enderby backcountryJanuary 24, 2023 | globalnews.caSecret CSO: Todd Dekkinga, Zluri - IDG ConnectJanuary 12, 2023 | news.google.comDon't Tell Anyone: Insiders Are Buying These Stocks Like CrazyDecember 28, 2022 | thestreet.comElixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board ... - GlobeNewswireDecember 21, 2022 | news.google.comGlobal Human Growth Hormones Deficiency (Ghd) Drug Market Upcoming Innovations, Companies, and Forec - PharmiWeb.comNovember 18, 2022 | news.google.comScrut Automation Hires Todd Dekkinga as Its Chief Information Security Officer - Press Trust of India - archive.ptinews.comOctober 21, 2022 | news.google.comTodd Dekkinga named Chief Information Security Officer at Zluri - Security MagazineOctober 12, 2022 | securitymagazine.comZluri Hires Todd Dekkinga as Chief Information Security Officer - PR WebOctober 11, 2022 | prweb.comZluri Hires Todd Dekkinga as Chief Information Security Officer - Yahoo FinanceOctober 11, 2022 | finance.yahoo.comPhase 3 flop puts Versartis on life support - FierceBiotechOctober 9, 2022 | fiercebiotech.comHuman Growth Hormones Deficiency (GHD) Drugs Market Prospects & Upcoming s and Opportunities Analyzed for Coming Years – This Is Ardee - This Is ArdeeJuly 25, 2022 | thisisardee.ieHuman Growth Hormones Deficiency (GHD) Drugs Market Revenue Growth, Key Players | Pharma A/S, Novo Nordisk A/S, Versartis Inc., Opko Health Inc. – Designer Women - Designer WomenJune 29, 2022 | designerwomen.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVSAR, AEHAW, NTHI, and NEXI Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.01 +0.00 (+5.26%) As of 05/23/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.NexImmune NASDAQ:NEXINexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Neonc Technologies NASDAQ:NTHI$7.22 -0.11 (-1.50%) As of 05/23/2025 04:00 PM EasternNeonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.Versartis NASDAQ:VSARAravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
